Hormona, a health tech startup focused on women’s hormonal wellbeing, has secured £5 million ($6.7 million) in seed funding to scale its operations and bring its AI-driven home testing solutions to a wider audience.
Founded in 2020 by Karolina Löfqvist and Jasmine Tagesson, Hormona has spent four years developing a new approach to hormone health, combining clinical-grade at-home testing with artificial intelligence to deliver highly accurate, real-time insights. The company is now preparing to launch its proprietary hormone tests, expand internationally, and build out its infrastructure, marketing and sales teams.
The funding round was led by Voima Ventures and co-led by SuperNode Global VC. As part of the deal, Voima’s Inka Mero and SuperNode’s Gina King will join Hormona’s all-female board, supporting its strategic direction and long-term growth.
Hormona is focused on addressing a critical gap in healthcare. While 80% of women face hormone-related challenges during their lives, only 2% of global medical funding is dedicated to research in women-specific health concerns. The company’s mission is to give users better tools and understanding to manage these often-overlooked conditions.
CEO Karolina Löfqvist shared her personal motivation behind the venture, recounting how her own hormonal condition went undiagnosed for years despite persistent medical consultations. Her experience led to the creation of Hormona, working closely with specialists in endocrinology, gynecology, and nutrition to ensure a clinically informed product.
The app, which is currently being used in nearly 200 countries, provides educational resources and personalized hormone tracking. The company claims over 90% accuracy with its tests, compared to traditional blood sampling methods, making it a reliable and more accessible alternative for millions of women.
“For too long, women have had to suffer through hormonal issues, relying on trial and error and waiting until symptoms become unbearable. That’s no way to live,” said Löfqvist. “We built Hormona to change that – to give women control over their hormonal health without having to spend years suffering, as I did. This investment brings us one step closer to making real-time hormone tracking accessible to women everywhere without the need for multiple blood draws. We’re proud to be leading the way and improving women’s health, one user at a time.”
Investor Inka Mero of Voima Ventures commented on the significance of the investment: “At Voima Ventures, we seek out visionary teams and bold science that can redefine entire industries, and Hormona is exactly that: they are pioneering a global movement in women’s health. By tackling one of the most overlooked yet fundamental aspects of women’s well-being – hormonal health – they are giving millions of women the tools, data, and empowerment to take control of their bodies and lives. We are incredibly proud to stand beside Hormona as they lead this health revolution.”
As Hormona sets its sights on global growth, the latest round of funding is expected to fast-track the rollout of its innovative hormone testing and educational tools to a broader audience, placing hormone health more squarely in the spotlight of women’s wellness.
